222 related articles for article (PubMed ID: 19762515)
1. Examining the involvement of erythropoiesis-stimulating agents in tumor proliferation (erythropoietin receptors, receptor binding, signal transduction), angiogenesis, and venous thromboembolic events.
Fandrey J; Dicato M
Oncologist; 2009; 14 Suppl 1():34-42. PubMed ID: 19762515
[TBL] [Abstract][Full Text] [Related]
2. Venous thromboembolic events and erythropoiesis-stimulating agents: an update.
Dicato M
Oncologist; 2008; 13 Suppl 3():11-5. PubMed ID: 18458119
[TBL] [Abstract][Full Text] [Related]
3. Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients.
Sinclair AM; Todd MD; Forsythe K; Knox SJ; Elliott S; Begley CG
Cancer; 2007 Aug; 110(3):477-88. PubMed ID: 17582631
[TBL] [Abstract][Full Text] [Related]
4. Tumor progression associated with erythropoiesis-stimulating agents.
Newland AM; Black CD
Ann Pharmacother; 2008 Dec; 42(12):1865-70. PubMed ID: 19017828
[TBL] [Abstract][Full Text] [Related]
5. Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms.
Hadland BK; Longmore GD
J Clin Oncol; 2009 Sep; 27(25):4217-26. PubMed ID: 19636005
[TBL] [Abstract][Full Text] [Related]
6. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.
Juneja V; Keegan P; Gootenberg JE; Rothmann MD; Shen YL; Lee KY; Weiss KD; Pazdur R
Clin Cancer Res; 2008 Jun; 14(11):3242-7. PubMed ID: 18519748
[TBL] [Abstract][Full Text] [Related]
7. The erythropoietin receptor in normal and cancer tissues.
Jelkmann W; Bohlius J; Hallek M; Sytkowski AJ
Crit Rev Oncol Hematol; 2008 Jul; 67(1):39-61. PubMed ID: 18434185
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin receptors on tumor cells: what do they mean?
Fandrey J
Oncologist; 2008; 13 Suppl 3():16-20. PubMed ID: 18458120
[TBL] [Abstract][Full Text] [Related]
9. Erythropoiesis-stimulating agents for anemic patients with cancer.
Sheikh S; Littlewood TJ
Expert Rev Hematol; 2010 Dec; 3(6):697-704. PubMed ID: 21091146
[TBL] [Abstract][Full Text] [Related]
10. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
Nowrousian MR; Dunst J; Vaupel P
Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin in cancer patients: pros and cons.
Dicato M; Plawny L
Curr Opin Oncol; 2010 Jul; 22(4):307-11. PubMed ID: 20498598
[TBL] [Abstract][Full Text] [Related]
12. Anemia management in oncology and hematology.
Spivak JL; Gascón P; Ludwig H
Oncologist; 2009; 14 Suppl 1():43-56. PubMed ID: 19762516
[TBL] [Abstract][Full Text] [Related]
13. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
[TBL] [Abstract][Full Text] [Related]
14. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression.
Hedley BD; Allan AL; Xenocostas A
Clin Cancer Res; 2011 Oct; 17(20):6373-80. PubMed ID: 21750199
[TBL] [Abstract][Full Text] [Related]
15. Erythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives.
Arcasoy MO
Clin Cancer Res; 2008 Aug; 14(15):4685-90. PubMed ID: 18676735
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin in cancer patients.
Glaspy JA
Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468
[TBL] [Abstract][Full Text] [Related]
17. Erythropoiesis stimulating agents, thrombosis and cancer.
Barbera L; Thomas G
Radiother Oncol; 2010 Jun; 95(3):269-76. PubMed ID: 20219259
[TBL] [Abstract][Full Text] [Related]
18. Update on erythropoiesis-stimulating agents and clinical trials in oncology.
Aapro M; Spivak JL
Oncologist; 2009; 14 Suppl 1():6-15. PubMed ID: 19762512
[TBL] [Abstract][Full Text] [Related]
19. The role of the pharmacist in optimizing the use of erythropoietin stimulating agents.
Gebara SN; Moubayed H
J Oncol Pharm Pract; 2010 Mar; 16(1):33-7. PubMed ID: 19401308
[TBL] [Abstract][Full Text] [Related]
20. Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia.
Osterborg A; Aapro M; Cornes P; Haselbeck A; Hayward CR; Jelkmann W
Eur J Cancer; 2007 Feb; 43(3):510-9. PubMed ID: 17150352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]